AR023391A1 - Composicion que contiene carnitina e inositol fosfato, util como suplemento dietario o droga - Google Patents

Composicion que contiene carnitina e inositol fosfato, util como suplemento dietario o droga

Info

Publication number
AR023391A1
AR023391A1 ARP000101562A ARP000101562A AR023391A1 AR 023391 A1 AR023391 A1 AR 023391A1 AR P000101562 A ARP000101562 A AR P000101562A AR P000101562 A ARP000101562 A AR P000101562A AR 023391 A1 AR023391 A1 AR 023391A1
Authority
AR
Argentina
Prior art keywords
dietary supplement
inositol phosphate
drug
useful
composition containing
Prior art date
Application number
ARP000101562A
Other languages
English (en)
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of AR023391A1 publication Critical patent/AR023391A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Una composicion adecuada para la prevencion y/o tratamiento de trastornos cardiovasculares y neurocerebrales , formas anoxicas de tejido, deficiencias deenergía muscular, anormalidades de tipo inflamatoria, alteraciones de coagulacion de sangre,tale s como trombosis y formas de proliferacion de tejidos, quepueden tomar la forma de un suplemento dietario, soporte dietético o de un medicamento real, que comprende ingredientes activos caracterizantes: a) propionilL-carnitina o una salfarmacologica mente aceptable de la misma; y b) un inositol fosfato, particularmente el inositol hexafosfato (IP6).
ARP000101562A 1999-04-22 2000-04-05 Composicion que contiene carnitina e inositol fosfato, util como suplemento dietario o droga AR023391A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999RM000248A IT1306133B1 (it) 1999-04-22 1999-04-22 Composizione comprendente una carnitina ed un inositolfosfato, utilequale integratore dietetico o medicamento.

Publications (1)

Publication Number Publication Date
AR023391A1 true AR023391A1 (es) 2002-09-04

Family

ID=11406708

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101562A AR023391A1 (es) 1999-04-22 2000-04-05 Composicion que contiene carnitina e inositol fosfato, util como suplemento dietario o droga

Country Status (26)

Country Link
US (1) US6565876B1 (es)
EP (1) EP1119363B1 (es)
JP (1) JP2002542282A (es)
KR (1) KR20010053023A (es)
CN (1) CN1359295A (es)
AR (1) AR023391A1 (es)
AT (1) ATE299370T1 (es)
AU (1) AU776591B2 (es)
BR (1) BR0006076A (es)
CA (1) CA2335015C (es)
DE (1) DE60021247T2 (es)
DK (1) DK1119363T3 (es)
EE (1) EE200000742A (es)
ES (1) ES2243254T3 (es)
HU (1) HU227357B1 (es)
IL (1) IL140164A0 (es)
IS (1) IS5763A (es)
IT (1) IT1306133B1 (es)
NO (1) NO20006429L (es)
PL (1) PL197885B1 (es)
PT (1) PT1119363E (es)
SI (1) SI1119363T1 (es)
SK (1) SK19322000A3 (es)
TN (1) TNSN00083A1 (es)
TR (1) TR200003737T1 (es)
WO (1) WO2000064426A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1316997B1 (it) * 2000-03-02 2003-05-26 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di vasculopatie,che comprende propionil l-carnitina e coenzima q10.
DE10032964B4 (de) * 2000-07-06 2017-10-12 Beiersdorf Ag Verwendung von Kreatin in kosmetischen oder dermatologischen Zubereitungen
DE10129502A1 (de) * 2001-06-19 2003-01-09 Beiersdorf Ag Verwendung von Carnitin und/oder einem oder mehreren Acyl-Carnitinen zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Steigerung der Ceramidbiosynthese
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
US20090169585A1 (en) * 2003-10-23 2009-07-02 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
PL1863495T3 (pl) * 2005-03-18 2015-06-30 Normoxys Inc Sól wapniowa 1,6:2,3:4,5-tripirofosforanu mioinozytolu jako efektor allosteryczny hemoglobiny w leczeniu raka
ES2280136B1 (es) * 2006-02-17 2008-08-16 Universitat De Les Illes Balears Asociacion a dosis fija de fitato y zinc.
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
JP5281268B2 (ja) * 2007-10-31 2013-09-04 花王株式会社 筋力向上剤
EA019237B1 (ru) * 2008-11-11 2014-02-28 Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. Соединения, пригодные для лечения целлюлита
CA2801281C (en) * 2010-06-16 2018-07-10 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue
ES2495666B1 (es) * 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
KR102141971B1 (ko) * 2018-11-12 2020-08-06 주식회사 노암 항암용 조성물
TW202110437A (zh) * 2019-05-23 2021-03-16 美商希諾瓦有限責任公司 用於酒精誘發之皮膚潮紅之治療及緩解的組成物及方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626849A (en) * 1995-06-07 1997-05-06 Reliv International, Inc. Weight loss composition for burning and reducing synthesis of fats
JP2001511153A (ja) * 1997-02-04 2001-08-07 ブイ． コスバブ，ジョン 血管変性性疾患の予防および処置のための組成物および方法
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US5904924A (en) * 1997-11-04 1999-05-18 Oncologics, Inc. Green nutritional powder composition

Also Published As

Publication number Publication date
PL346160A1 (en) 2002-01-28
DE60021247D1 (de) 2005-08-18
KR20010053023A (ko) 2001-06-25
NO20006429D0 (no) 2000-12-15
ES2243254T3 (es) 2005-12-01
CA2335015C (en) 2008-03-18
ITRM990248A1 (it) 2000-10-22
BR0006076A (pt) 2001-03-20
HUP0102926A2 (hu) 2002-03-28
US6565876B1 (en) 2003-05-20
DK1119363T3 (da) 2005-10-17
WO2000064426A3 (en) 2001-05-25
ATE299370T1 (de) 2005-07-15
DE60021247T2 (de) 2006-04-27
NO20006429L (no) 2001-02-20
CA2335015A1 (en) 2000-11-02
AU776591B2 (en) 2004-09-16
IT1306133B1 (it) 2001-05-30
IS5763A (is) 2000-12-08
CN1359295A (zh) 2002-07-17
JP2002542282A (ja) 2002-12-10
WO2000064426A2 (en) 2000-11-02
SI1119363T1 (en) 2005-10-31
IL140164A0 (en) 2002-02-10
SK19322000A3 (sk) 2001-06-11
PT1119363E (pt) 2005-09-30
EP1119363B1 (en) 2005-07-13
TNSN00083A1 (fr) 2005-11-10
PL197885B1 (pl) 2008-05-30
HU227357B1 (en) 2011-04-28
TR200003737T1 (tr) 2001-07-23
HUP0102926A3 (en) 2002-12-28
AU4313500A (en) 2000-11-10
EE200000742A (et) 2002-04-15
EP1119363A2 (en) 2001-08-01

Similar Documents

Publication Publication Date Title
AR023391A1 (es) Composicion que contiene carnitina e inositol fosfato, util como suplemento dietario o droga
AR022076A1 (es) Composicion antioxidante constituida por acetil l-carnitina y acido alfa-lipoico para mejorar el aprovechamiento metabolico de la glucosa
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
ES2191192T3 (es) Tienopirimidinas.
CO5160320A1 (es) Metodos y composiciones para la prevencion de tolerancia a medicamentos das.
ATE321529T1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
PT1465504E (pt) Composicao que contem pectina para formar uma matriz
DK1576970T3 (da) Intraluminal indretning med en coating, der indeholder et terapeutisk middel
NZ541593A (en) Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
BR0112962A (pt) Composições farmacêuticas para o tratamento de condições inflamatórias e ulcerativas dolorosas de maioria das superfìcies epiteliais tais como mucosite, estomatite e sìndrome de behcet
PT1071439E (pt) Formulacoes de fruto da roseira como farmaco natural anti-inflamatorio para aliviar/reduzir os sintomas associados a inflamacao e artrite
AR028959A1 (es) Uso de rapamicina para la manufactura de un medicamento para tratar enfermedades cardiovasculares
BRPI0406484A (pt) Método de inibição da ocorrência de uma ou mais das seguintes condições: a proliferação de monócitos/macrófagos; ou a proliferação de células do músculo liso; ou a expressão de receptores de cd36; ou a absorção de lipoproteìna de baixa densidade - ldl oxidada, método de alìvio de sintomas de tratamento ou prevenção de aterosclerose; de diabetes; do mal de alzheimer, método de inibição da ocorrência da formação de placas no sistema vascular, método de alìvio da inflamação associada a ocorrência de uma ou de mais das seguintes condições: a proliferação de monócitos, a proliferação de células do músculo liso, a expressão de ldl oxidadas ou de receptor descontaminante, composição farmacêutica, uso de uma quantidade eficaz de um ou mais derivados ou fosfato de um ou mais agentes de transferência de elétrons conjuntamente com um veìculo ou um diluente apropriado, uso de uma quantidade eficaz de um ou mais derivados de fosfato de (alfa)-tocoferol conjuntamente com um veìculo ou um diluente apropriado e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons selecionados do grupo que consiste em fosfato mono-tocoferila, fosfato de di-tocoferila e as misturas destes conjuntamente com um veìculo ou um diluente apropriado
PT1893237E (pt) Composição farmacêutica compreendendo um elastómero organopolissiloxano e um princípio activo solubilizado
PL330865A1 (en) Agents containing lectins and their application
BRPI0415290A (pt) uso terapêutico de variantes de quimiocina
AR024564A1 (es) Composicion que comprende esfingomielinasa para el uso como una preparacion dietetica, suplemento dietario o producto farmaceutico
AR021172A1 (es) Composicion antiprolifica, antioxidante, que comprende una carnitina y un carotenoide
AR019737A4 (es) Composicion antioxidante, citostatica y de energia sostenida que mejora la utilizacion metabolica de glucosa
AR040737A1 (es) Administracion oral de calcitonina
TW200505408A (en) Agent for preventing and/or treating tissue disruption-accompanied diseases
BR9607996A (pt) Derivado de aminotetralina para o tratamento de doenças cardiovasculares
SE8403659D0 (sv) Synergistic pharmaceutical composition
ES2156446T3 (es) Formulacion farmaceutica semisolida que contiene dexketoprofeno trometanol.
ES2196171T3 (es) Agentes antitumorales de tioxantenona liofilizada.